Sangamo, in Chapter 11, agrees to sell ST-920 Fabry gene therapy assets to PTC for USD 111 million upfrontPUBT·Aug 28 at 08:06 PMSGMOQ-3.13%PTC-6.04%
The Algorithm's Leftovers: From Bankrupt Genomics to New VC Funds in the Market's EdgesGlobal Report·Aug 25 at 10:12 AMRVI+1.00%AACBR0.00%
Sangamo selects winning bids in Chapter 11 asset auction for USD 163.55 million cash at closePUBT·Aug 12 at 08:28 PMSGMOQ-3.13%LLY-0.88%
The Sub-Radar Shakeup: AI Acquisitions, Navy Contracts, and Biotech OverhaulsGlobal Report·Aug 11 at 10:13 AMPRGS-1.26%SGMOQ-3.13%
The Currents Beneath Big Tech: How Niche Markets are Surviving the 2026 FragmentationGlobal Report·Aug 4 at 09:17 AMNXT+1.20%ROK+1.29%
Sangamo loses Nasdaq listing appeal after minimum bid price breachPUBT·Jul 20 at 08:45 PMSGMOQ-3.13%SGMO0.00%
Sangamo Therapeutics ends Ernst & Young as auditor after Chapter 11 filingPUBT·Jul 1 at 08:01 PMSGMOQ-3.13%
